Evaluation of Neuroprotective Activity of Wedelolactone and Gallic Acid on the Pathogenesis of Amyotrophic Lateral Sclerosis

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, multisystemic neurodegenerative disease with evidence of motor neuron loss in the brain and spinal cord. The factors behind the ALS are genetic, oxidative stress, glutamate excitotoxicity, protein aggregation, apoptosis, autoimmunity, production of inflammatory cytokines, alteration in a cellular process, metabolic impairment, mitochondrial damage, glial activation, and disruption in axonal transport. The multiple pathogeneses behind the development and progression of ALS make a challenge to find out an effective therapy for this disease. This study aims to unravel the mechanisms behind the neuroprotective effects of wedelolactone and gallic acid against aluminium-induced neurodegeneration and thereby to unlock a platform to find a cure for sALS.